WO2011060144A3 - Compositions and methods to protect cells by blocking entry of pathogen proteins - Google Patents

Compositions and methods to protect cells by blocking entry of pathogen proteins Download PDF

Info

Publication number
WO2011060144A3
WO2011060144A3 PCT/US2010/056351 US2010056351W WO2011060144A3 WO 2011060144 A3 WO2011060144 A3 WO 2011060144A3 US 2010056351 W US2010056351 W US 2010056351W WO 2011060144 A3 WO2011060144 A3 WO 2011060144A3
Authority
WO
WIPO (PCT)
Prior art keywords
polar lipids
motifs
cell
compositions
methods
Prior art date
Application number
PCT/US2010/056351
Other languages
French (fr)
Other versions
WO2011060144A2 (en
Inventor
Brett Tyler
Shiv Kale
Vincenzo Antignani
Original Assignee
Virginia Tech Intellectual Properties, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties, Inc. filed Critical Virginia Tech Intellectual Properties, Inc.
Publication of WO2011060144A2 publication Critical patent/WO2011060144A2/en
Publication of WO2011060144A3 publication Critical patent/WO2011060144A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2410/00—Assays, e.g. immunoassays or enzyme assays, involving peptides of less than 20 animo acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Pathogenic effector proteins include one or more virulence motifs of amino acid consensus sequence BXZ, where B = RK or H; X = any amino acid or is absent; Z = L, M, I, W, Y or F) which bind to target polar lipids on a host (plant or animal) cell as a prerequisite for translocation of the pathogenic effector proteins into the cell. Translocation is prevented by binding blocking compounds to one or more motifs of the effector protein or to the lipid Iigands of the host cell. The blocking compounds include synthetic or naturally occurring polypeptides which bind the polar lipids or the motifs, various polar lipids, the hydrophilic head-groups of polar lipids, etc. Suitable blocking compounds can be identified by assays demonstrating binding to the motifs or to the target polar lipids.
PCT/US2010/056351 2009-11-11 2010-11-11 Compositions and methods to protect cells by blocking entry of pathogen proteins WO2011060144A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26022709P 2009-11-11 2009-11-11
US61/260,227 2009-11-11

Publications (2)

Publication Number Publication Date
WO2011060144A2 WO2011060144A2 (en) 2011-05-19
WO2011060144A3 true WO2011060144A3 (en) 2011-09-29

Family

ID=43992395

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/056351 WO2011060144A2 (en) 2009-11-11 2010-11-11 Compositions and methods to protect cells by blocking entry of pathogen proteins

Country Status (1)

Country Link
WO (1) WO2011060144A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102533852A (en) * 2012-02-24 2012-07-04 南京农业大学 Application of phytophthora sojae gene PsIR1 capable of inducing plant disease resistance
CN107881254A (en) * 2017-12-18 2018-04-06 福建省农业科学院植物保护研究所 Loop-mediated isothermal amplification method detects the primer and its detection method of ramie mould bacterium
IT201900008529A1 (en) * 2019-06-10 2020-12-10 Edmund Mach Fond Peptides with fungicidal activity, their compositions and related uses in the agronomic field
CN110804615B (en) * 2019-11-04 2021-06-29 山东农业大学 Phytophthora capsici effector RxLR553394 gene and application thereof
CN110840901A (en) * 2019-12-12 2020-02-28 南京大学 Application of lysophosphatidylethanolamine 18:1 in preparation of medicines for relieving and treating inflammatory bowel diseases
CN113121659B (en) * 2021-04-23 2021-10-22 南京林业大学 Phytophthora camphora effector protein Avh57 and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032308A1 (en) * 2000-05-18 2002-03-14 Strobel Gary A. Oocydin and methods of use for protection of plants from Oomyocyte pathogens
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020032308A1 (en) * 2000-05-18 2002-03-14 Strobel Gary A. Oocydin and methods of use for protection of plants from Oomyocyte pathogens
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIRCH ET AL.: "Trafficking arms: oomycete effectors enter host plant cells", TRENDS IN MICROBIOLOGY, vol. 14, no. 1, 13 December 2005 (2005-12-13), pages 8 - 11, XP025014094, DOI: doi:10.1016/j.tim.2005.11.007 *
MORGAN ET AL. ET AL.: "RXLR effectors of plant pathogenic oomycetes", CURRENT OPINION IN MICROBIOLOGY, vol. 10, no. 4, 17 August 2007 (2007-08-17), pages 332 - 338, XP022257610, DOI: doi:10.1016/j.mib.2007.04.005 *

Also Published As

Publication number Publication date
WO2011060144A2 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
WO2011060144A3 (en) Compositions and methods to protect cells by blocking entry of pathogen proteins
WO2009143133A3 (en) Compositions and methods to protect cells by blocking entry of pathogen proteins
WO2012101599A3 (en) Glycogen synthase kinase-3 inhibitors
CA2835644C (en) Pre-fusion rsv f antigens
WO2010088517A8 (en) Methods and systems for purifying transferring and/or manipulating nucleic acids
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2013051878A3 (en) Antibody specifically binding to epitope in sema domain of c-met
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
IN2014CN00414A (en)
EP3970746A3 (en) Polypeptide variants and uses thereof
WO2014106015A3 (en) Multivalent binding protein compositions
EA201370076A1 (en) IMMUNE GLOBULIN TRANSFER AND THEIR APPLICATION
CR11282A (en) PROTEINS LINKED TO THE HUMAN FELINO MCDONOUGH CEPA CELL ANTIGEN
BR112012029588A2 (en) her3-related biological materials.
AU2012257942A8 (en) Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same
WO2011156529A3 (en) Methods and composition for multiplex sequencing
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2007143574A8 (en) Protein surface remodeling
WO2012142591A3 (en) Compositions, methods and uses for multiplex protein sequence activity relationship mapping
CL2013002361A1 (en) Method to measure natural killer cell activity (nk); kit to measure said activity; fusion protein; composition for activating nk cells; polypeptide, oligonucleotide, vector and host cell comprising the protein;
WO2012013930A3 (en) Process for purifying proteins
WO2008104890A3 (en) Compositions and methods for producing apolipoprotein
WO2011146595A3 (en) Zwitterionic reagents
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10830711

Country of ref document: EP

Kind code of ref document: A2